Aktienanalyse zu AngioDynamics, Inc. (ANGO)ANGOAngioDynamics, Inc.

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. The Med Tech segment is comprised of its technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment includes its Core, Venous, Ports and other Oncology products. Its product types are Ablation, Catheters, Medical Balloons, and Ports. The Catheter products include Angiographic Catheters, Uni-Fuse Infusion Catheter and Drainage Catheters. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

AngioDynamics is not a good buy right now due to its current price of $11.24, which is significantly below the analyst price targets of $19 and $20. The RSI is at 27.34, indicating that the stock is oversold, but the company has reported continuous losses, including a net loss of $11.4 million in Q4 2026, which raises concerns about its profitability. The forward P/E ratio is extremely high at 96.15, suggesting that the stock is overvalued relative to its earnings potential. The main risk is the projected loss per share of $0.24 to $0.29 for fiscal 2027, indicating ongoing financial challenges.

5 analysts cover ANGO: 1 rate it Buy, 4 Hold and 0 Sell. The average price target is 19.33.